IBBM   21076
INSTITUTO DE BIOTECNOLOGIA Y BIOLOGIA MOLECULAR
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Outer membrane vesicles obtained from Bordetella pertussisTohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate
Autor/es:
GAILLARD ME.; ASENSIO,CRISTIANJ; GRISELDA MORENO; BOTTERO D; MARTÍN RUMBO; VANDERLEY,PETER; VANDERARK,2ARNO; HOZBOR D.
Lugar:
Buenos Aires - Argentina
Reunión:
Congreso; First French-Argentine Inmunology Congress; 2010
Resumen:
Outer membrane vesicles obtained from Bordetella pertussis Tohama
expressing the lipid A deacylase PagL as a novel acellular vaccine candidate.
Gaillard,1María Emilia; Asensio,
Cristian J.; Moreno,3Griselda; Bottero, Daniela; Rumbo,3 Martin; van der
Ley,2 Peter; van der Ark,2Arno; Hozbor, Daniela.
1 Instituto de Biotecnología y Biología Molecular (IBBM). Facultad de
Ciencias Exactas. Universidad Nacional de La Plata. Centro Científico
Tecnológico CONICET La Plata. Calles 47 y 115. 1900. La Plata. Argentina.
2 Netherlands Vaccine Institute, 3720 AL Bilthoven, The Netherlands
3 Laboratorio de Investigaciones del Sistema Inmune (LISIN). Facultad de
Ciencias Exactas, UNLP 47 y 115 (1900) La Plata, Argentina
Affiliation
megaillard@biol.unlp.edu.ar
In an effort to devise a safer and
effective pertussis acelullar vaccine, outer membrane vesicles (OMVs) were
engineered to decrease their endotoxicity. The pagL gene from Bordetella
bronchiseptica, which encodes a lipid A 3-deacylase, was expressed in B.
pertussis strain Tohama I. The resulting OMVs, designated OMVsPagL, contain
tetra- instead of penta-acylated LPS, in addition to pertussis surface
immunogens such as pertactin and pertussis toxin, as the wild type OMVs. The
characterized pertussis OMVsPagL were used in murine B. pertussis intranasal
(i.n.) challenge model to examine their protective capacity when delivered by
i.n routes. Immunized BALB/c mice were challenged with sublethal doses of B.
pertussis. Significant differences between immunized animals and the PBS
treated group were observed (p < 0.001). Adequate elimination rates (p
< 0.005) were observed in mice immunized either with OMVsPagL and wild
type OMVs. All OMV preparations tested were non toxic according to WHO
criteria; however, OMVsPagL displayed almost no weight loss at 3 days post
administration, indicating less toxicity when compared with wild type OMVs.
Induction of IL6- and IL1 expression in lung after i.n. delivery showed coincident
results, with a lower induction of the proinflammatory cytokines in the case
of OMVsPagL compared to wild type OMVs.
In view to their lower endotoxic
activity and retained protective capacity in the mouse model, OMVsPagL obtained
from B pertussis are candidates for novel vaccines against pertussis.